Patents by Inventor Roger Baurain
Roger Baurain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7951772Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.Type: GrantFiled: June 10, 2008Date of Patent: May 31, 2011Assignees: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Publication number: 20090137494Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.Type: ApplicationFiled: June 10, 2008Publication date: May 28, 2009Applicants: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Patent number: 7390629Abstract: Methods of screening and identifying tumor-activated prodrug forms of therapeutic agents are described.Type: GrantFiled: March 8, 2006Date of Patent: June 24, 2008Assignees: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Publication number: 20060148682Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.Type: ApplicationFiled: March 8, 2006Publication date: July 6, 2006Applicants: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Patent number: 7037898Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.Type: GrantFiled: November 9, 2001Date of Patent: May 2, 2006Assignees: LaRegion Wallone, Universite Catholique de LouvainInventors: André Trouet, Roger Baurain
-
Publication number: 20020160943Abstract: The compound (W—Z—M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W—Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W—Z) and the component (M) prevents intracellular entry of the compound (W—Z—M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W—Z—M) in the serum and circulating blood.Type: ApplicationFiled: November 9, 2001Publication date: October 31, 2002Inventors: Andre Trouet, Roger Baurain
-
Patent number: 6342480Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (Z) linked to a terminal group (W), characterized in that the linkage between the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and circulating blood.Type: GrantFiled: April 23, 1999Date of Patent: January 29, 2002Assignees: La Region Wallone, Universite Catholique de LouvainInventors: André Trouet, Roger Baurain
-
Patent number: 5962216Abstract: The compound (W-Z-M) according to the invention comprises a component (M) chosen from the group consisting of markers and therapeutic agents possessing an intracellular active site (A.S.), linked to a ligand (W-Z) comprising an arm (z) linked to a terminal group (W), characterized in that the linkage in the arm (Z) of the ligand (W-Z) and the component (M) prevents intracellular entry of the compound (W-Z-M) and/or inhibits expression of the marker (M), in that said linkage can be selectively cleaved by factors secreted by target cells so as to permit expression of the marker (M) or entry of the therapeutic agent (M) into said target cells, and in that the terminal group (W) provides for the stability of the compound (W-Z-M) in the serum and the circulating blood.Type: GrantFiled: April 1, 1997Date of Patent: October 5, 1999Assignees: La Region Wallonne, Universite Catholique de LouvainInventors: Andre Trouet, Roger Baurain
-
Patent number: 4973465Abstract: The present invention relates to microcrystals of a substance, which substance is insoluble in water and has an affinity for phospholipids, as well as a process for its preparation. According to the invention, one or more organic solvents are evaporated from a solution of phospholipids and substance, and the film obtained thereby, after evaporation of the one or more solvents, is suspended in an aqueous solution by vigorous stirring. The invention also relates to pharmaceutical compositions containing as active principle these microcrystals, particularly liquid pharmaceutical compositions packaged in injectable form or in sprayable form.Type: GrantFiled: June 8, 1989Date of Patent: November 27, 1990Assignee: Ire-Celltarg S.A.Inventors: Roger Baurain, Andre B. L. Trouet